ArticleMolecular neurobiology2025
Bidirectional Causal Associations Between Plasma Metabolites and Parkinson's Disease.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring the impacts of type 2 diabetes and metformin use on Parkinson's disease: Mendelian randomization analysis and a national cohort study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Exploring the Fecal Microbiome Dysbiosis and Its Plasma Metabolome Determinants in Advanced Parkinson's Disease With Motor Complications.CNS neuroscience & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In plasma samples of patients with neuropsychitraic disorders, the levels of many metabolites differ from those in healthy controls. Causal connections between Parkinson's disease (PD), one of the most prevalent degenerative disorders, and the levels of plasma metabolites remain unclear. Bidirectional metabolome-wide Mendelian randomization (MR) analysis was performed to explore the potential causative associations between PD in a genome-wide association study (GWAS) dataset with 5,150 cases and 448,583 controls, and the levels of 871 plasma circulating metabolites (N = 8,299). The MR analysis detected 38 metabolites associated with PD. Fourteen of these metabolites were associated with a reduced risk of PD (odds ratio (OR): 0.86-0.92), along with 24 metabolites contributing to elevated risks of PD (OR: 1.06-1.23). In reverse MR analysis, genetic signature of PD had positive causal effects on the levels of 35 circulating metabolites (OR: 1.04-1.07) and negative causal effects on the levels of 13 metabolites (OR: 0.94-0.96). For three circulating metabolites levels, including behenoyl dihydrosphingomyelin (d18:0/22:0), 1-stearoyl-GPE (18:0) as well as N-palmitoyl-sphingadienine (d18:2/16:0), bi-directional causative relationships with PD were uncovered. Our findings revealed a network of bidirectional causal associations between the levels of individual plasma metabolites and the risks of PD, providing possible clues for the prevention and the therapy of this disorder.
Indexed as
Identifiers
41222837What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.